X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3450) 3450
Book Review (520) 520
Publication (142) 142
Newsletter (19) 19
Magazine Article (13) 13
Book Chapter (3) 3
Conference Proceeding (2) 2
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3034) 3034
humans (2760) 2760
male (1658) 1658
lovastatin (1656) 1656
lovastatin - therapeutic use (1609) 1609
female (1460) 1460
middle aged (1265) 1265
simvastatin (1077) 1077
anticholesteremic agents - therapeutic use (927) 927
adult (906) 906
aged (827) 827
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (742) 742
hypercholesterolemia - drug therapy (740) 740
cholesterol (727) 727
statins (706) 706
animals (679) 679
abridged index medicus (658) 658
pharmacology & pharmacy (636) 636
lovastatin - analogs & derivatives (615) 615
cholesterol - blood (601) 601
lovastatin - pharmacology (570) 570
cholesterol, ldl - blood (544) 544
pravastatin (510) 510
hypercholesterolemia (449) 449
cardiac & cardiovascular systems (386) 386
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (370) 370
triglycerides - blood (362) 362
hypercholesterolemia - blood (334) 334
treatment outcome (328) 328
double-blind method (322) 322
hydroxymethylglutaryl-coa reductase inhibitors (322) 322
medicine, general & internal (318) 318
lovastatin - adverse effects (313) 313
risk factors (310) 310
drug therapy (299) 299
cholesterol, hdl - blood (293) 293
pravastatin - therapeutic use (291) 291
hypolipidemic agents - therapeutic use (286) 286
lipids - blood (285) 285
hyperlipidemias - drug therapy (284) 284
therapy (270) 270
lovastatin - administration & dosage (268) 268
atorvastatin (267) 267
prevention (264) 264
drug therapy, combination (257) 257
simvastatin - therapeutic use (253) 253
lipids (251) 251
oncology (241) 241
hyperlipoproteinemia type ii - drug therapy (238) 238
rats (238) 238
mice (235) 235
risk (235) 235
dose-response relationship, drug (231) 231
atorvastatin calcium (221) 221
atherosclerosis (219) 219
hmg-coa reductase (216) 216
apoptosis (215) 215
cancer (205) 205
coronary disease - prevention & control (197) 197
peripheral vascular disease (197) 197
antilipemic agents (196) 196
coa reductase inhibitors (196) 196
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (196) 196
anticholesteremic agents - pharmacology (193) 193
time factors (192) 192
heptanoic acids - therapeutic use (187) 187
research (181) 181
efficacy (180) 180
anticholesteremic agents - adverse effects (177) 177
pyrroles - therapeutic use (174) 174
follow-up studies (170) 170
lipoproteins - blood (168) 168
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (167) 167
metabolism (159) 159
drug interactions (158) 158
clinical trials as topic (157) 157
analysis (154) 154
cell line, tumor (151) 151
disease (151) 151
in-vitro (151) 151
men (150) 150
plasma (150) 150
statin (150) 150
hyperlipidemia (148) 148
coenzyme-a reductase (146) 146
health aspects (146) 146
hyperlipoproteinemia type ii - blood (146) 146
fluvastatin (145) 145
coronary-heart-disease (144) 144
anticholesteremic agents - administration & dosage (143) 143
safety (142) 142
drugs (140) 140
coronary heart-disease (139) 139
biochemistry & molecular biology (138) 138
cardiovascular disease (137) 137
prospective studies (135) 135
medicine & public health (134) 134
randomized controlled trials as topic (134) 134
aged, 80 and over (133) 133
inhibition (133) 133
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3231) 3231
Italian (40) 40
German (38) 38
French (32) 32
Spanish (32) 32
Russian (27) 27
Polish (12) 12
Portuguese (12) 12
Japanese (11) 11
Chinese (10) 10
Danish (8) 8
Czech (7) 7
Dutch (7) 7
Norwegian (7) 7
Swedish (6) 6
Hungarian (3) 3
Finnish (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Pharmacological Research, ISSN 1043-6618, 09/2011, Volume 64, Issue 3, pp. 180 - 186
Statins, long known to be beneficial in conditions where dyslipidemia occurs by lowering serum cholesterol levels, also have been proposed for use in... 
Alzheimer disease | Pleiotropic functions | Statins | Statins as Janus molecules | OXIDATIVE STRESS | COA REDUCTASE INHIBITORS | CLINICAL-TRIAL COHORT | DRUG-INTERACTIONS | NITRIC-OXIDE SYNTHASE | MILD COGNITIVE IMPAIRMENT | CELL-DEATH | COENZYME Q | AMYLOID-BETA | PHARMACOLOGY & PHARMACY | AUTOIMMUNE-DISEASE | Fatty Acids, Monounsaturated - pharmacology | Lovastatin - pharmacology | Heptanoic Acids - therapeutic use | Humans | Heptanoic Acids - adverse effects | Neurodegenerative Diseases - drug therapy | Quinolines - pharmacology | Fluorobenzenes - pharmacology | Fatty Acids, Monounsaturated - therapeutic use | Fatty Acids, Monounsaturated - adverse effects | Pyrroles - adverse effects | Indoles - pharmacology | Pyrroles - therapeutic use | Heptanoic Acids - pharmacology | Lovastatin - therapeutic use | Lovastatin - adverse effects | Alzheimer Disease - drug therapy | Rosuvastatin Calcium | Pyrimidines - pharmacology | Cholesterol - metabolism | Sulfonamides - pharmacology | Atorvastatin Calcium | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Indoles - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Indoles - therapeutic use | Fluorobenzenes - adverse effects | Quinolines - therapeutic use | Fluorobenzenes - therapeutic use | Quinolines - adverse effects | Alzheimer's disease | Neuroprotection | Neurotoxicity | Neurodegenerative diseases | statins | Dyslipidemia | Clinical trials | Age | Cholesterol | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 513, Issue 7519, pp. 507 - 511
Gain-of-function mutations in the fibroblast growth factor receptor 3 gene (FGFR3) result in skeletal dysplasias, such as thanatophoric dysplasia and... 
APOPTOSIS | ACHONDROPLASIA | ACTIVATION | MULTIDISCIPLINARY SCIENCES | GROWTH-FACTOR RECEPTOR-3 | MICE | MUTATIONS | DWARFISM | EXPRESSION | PEPTIDE | CARTILAGE | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Chondrocytes - cytology | Lovastatin - pharmacology | Cartilage - pathology | Achondroplasia - pathology | Male | Cartilage - drug effects | Fluorobenzenes - administration & dosage | Thanatophoric Dysplasia - pathology | Fluorobenzenes - pharmacology | Receptor, Fibroblast Growth Factor, Type 3 - deficiency | Cartilage - cytology | Female | Cell Differentiation | Induced Pluripotent Stem Cells - cytology | Achondroplasia - drug therapy | Thanatophoric Dysplasia - genetics | Achondroplasia - genetics | Disease Models, Animal | Induced Pluripotent Stem Cells - pathology | Lovastatin - therapeutic use | Chondrocytes - pathology | Receptor, Fibroblast Growth Factor, Type 3 - genetics | Bone Development - drug effects | Pyrimidines - administration & dosage | Mice, Inbred C57BL | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Phenotype | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Thanatophoric Dysplasia - drug therapy | Mice | Fluorobenzenes - therapeutic use | Sulfonamides - administration & dosage | Achondroplasia | Radiography | Care and treatment | Usage | Analysis | Diagnosis | Protein kinases | Genotype & phenotype | Transcription factors | Disease | Mutation | Kinases | Patients | Statins | Index Medicus
Journal Article
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 03/2018, Volume 38, Issue 3, pp. 592 - 598
Journal Article
Circulation, ISSN 0009-7322, 03/2010, Volume 121, Issue 9, pp. 1069 - 1077
Background-Statin therapy in women without cardiovascular disease (CVD) is controversial, given the insufficient evidence of benefit. We analyzed sex-specific... 
Prevention | Women | Lipids | Meta-analysis | LOVASTATIN | lipids | CARDIAC & CARDIOVASCULAR SYSTEMS | meta-analysis | RANDOMIZED CONTROLLED-TRIAL | HYPERTENSIVE PATIENTS | AFCAPS/TEXCAPS | INDIVIDUALS | DENSITY-LIPOPROTEIN CHOLESTEROL | MEN | PERIPHERAL VASCULAR DISEASE | PRAVASTATIN | OUTCOMES | CORONARY-HEART-DISEASE | HEMATOLOGY | prevention | women | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Male | Risk | Fluorobenzenes - administration & dosage | Early Termination of Clinical Trials | Dyslipidemias - blood | Cholesterol, LDL - blood | Female | Stroke - epidemiology | Muscular Diseases - chemically induced | C-Reactive Protein - analysis | Myocardial Ischemia - epidemiology | Dyslipidemias - drug therapy | Stroke - prevention & control | Double-Blind Method | Comorbidity | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Myocardial Ischemia - prevention & control | Rosuvastatin Calcium | Treatment Outcome | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Pyrimidines - adverse effects | Sex Factors | Sulfonamides - adverse effects | Aged | Fluorobenzenes - adverse effects | Fluorobenzenes - therapeutic use | Myocardial Ischemia - surgery | Sulfonamides - administration & dosage | Demographic aspects | Sex factors in disease | Rosuvastatin | Dosage and administration | Research | Cardiovascular diseases | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2016, Volume 11, Issue 7, pp. e0158608 - e0158608
Purpose To examine HMG-CoA reductase inhibitor (statin) drug dispensing patterns to Nova Scotia Seniors' Pharmacare program (NSSPP) beneficiaries over a... 
C-REACTIVE PROTEIN | THERAPY | CHOLESTEROL | MULTIDISCIPLINARY SCIENCES | CARDIOVASCULAR-DISEASE | JUPITER TRIAL | PEOPLE | HEALTH | RISK-ASSESSMENT | PRIMARY PREVENTION | ROSUVASTATIN | Simvastatin - therapeutic use | Rosuvastatin Calcium - therapeutic use | Humans | Male | Lovastatin - supply & distribution | Atorvastatin Calcium - supply & distribution | Indoles - supply & distribution | Fatty Acids, Monounsaturated - therapeutic use | Aged, 80 and over | Female | Prescription Drugs - supply & distribution | Retrospective Studies | Pravastatin - therapeutic use | Atorvastatin Calcium - therapeutic use | Lovastatin - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - supply & distribution | Interrupted Time Series Analysis | Clinical Trials as Topic | Hypolipidemic Agents - supply & distribution | Simvastatin - supply & distribution | Health Knowledge, Attitudes, Practice | Pravastatin - supply & distribution | Prescription Drugs - therapeutic use | Nova Scotia | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Indoles - therapeutic use | Aged | Hypolipidemic Agents - therapeutic use | Fatty Acids, Monounsaturated - supply & distribution | Rosuvastatin Calcium - supply & distribution | Economic aspects | Aged patients | Care and treatment | Dosage and administration | Laws, regulations and rules | Statins | Availability | Time series analysis | Simvastatin | Time series | Dispensing | Data processing | Lovastatin | Cardiovascular disease | Insurance coverage | Pravastatin | Confidence intervals | Studies | Prescription drugs | Fluvastatin | Pharmacy | Atorvastatin | Population | Hydroxymethylglutaryl-CoA reductase | Trends | Pharmaceutical industry | Index Medicus
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 11/2015, Volume 113, Issue 10, pp. 1421 - 1426
Journal Article